Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11631174 | 0.70 | PDPK1 (0.47) | IDO1PDPK1CYP11B2ADRA1A | |
| SCHEMBL11631168 | 0.70 | PDPK1 (0.47) | IDO1PDPK1CYP11B2ADRA1A | |
| SCHEMBL28636065 | 0.70 | IDO1 (0.43) | IDO1PDPK1CYP11B2CA1CA2 | |
| SCHEMBL11882269 | 0.69 | IDO1 (0.40) | IDO1PDPK1CYP11B2CA1CA2 | |
| SCHEMBL9165650 | 0.66 | IDO1 (0.46) | IDO1PDPK1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL384149 | 0.66 | IDO1 (0.46) | IDO1PDPK1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL1567191 | 0.66 | PDPK1 (0.50) | IDO1PDPK1CYP11B2ADRA1A | |
| SCHEMBL21937667 | 0.66 | IDO1 (0.46) | IDO1PDPK1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL22391437 | 0.66 | IDO1 (0.50) | IDO1PDPK1CYP11B2CYP19A1CYP17A1 | |
| SCHEMBL1567129 | 0.66 | HTR1A (0.47) | IDO1PDPK1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627652-B1 | Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid | ALLERGAN, INC. | 2003-09-30 | — | — | US | disclosed |
| US-5475113-A | Treatment of skin disorders, skin cancer | ALLERGAN, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0682516-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| US-5455265-A | For mammals; skin disorders, cancer, inflammatory disease, cardiovascular diorders, autoimmune diseases and others | ALLERGAN, INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994017796-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |